1. Lipoprotein(a) levels in systemic lupus erythematosus.
- Author
-
Borba EF, Santos RD, Bonfa E, Vinagre CG, Pileggi FJ, Cossermelli W, and Maranhão RC
- Subjects
- Adult, Antibodies, Anticardiolipin blood, Female, Humans, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic immunology, Lupus Nephritis blood, Lupus Nephritis etiology, Male, Middle Aged, Prednisone therapeutic use, Proteinuria blood, Proteinuria etiology, Risk Factors, Thrombosis blood, Thrombosis etiology, Vasculitis blood, Vasculitis etiology, Lipoprotein(a) blood, Lupus Erythematosus, Systemic blood
- Abstract
Objective: To determine lipoprotein(a) [Lp(a)] levels in systemic lupus erythematosus (SLE) and its possible correlation with thrombosis, disease activity, anticardiolipin antibodies (aCL) and steroid therapy., Methods: Serum Lp(a) levels were determined by radioimmunoassay (RIA) in 34 Caucasian patients with SLE and compared to 66 healthy subjects., Results: In patients with SLE Lp(a) levels were higher than in controls (42 +/- 35 vs 26 +/- 25 mg/dl, p = 0.01). Lp(a) levels were high (> or = 30 mg/dl) in 56% of the patients with SLE and in 30% of controls (p = 0.02) but were not correlated with the clinical and laboratory findings., Conclusions: Lp(a) levels are significantly higher in patients with SLE and are not influenced by disease activity, thrombosis, aCL and steroid therapy.
- Published
- 1994